Major changes in the sphingophospholipidome of HDL in non-diabetic patients with metabolic syndrome

Archive ouverte

Denimal, Damien | Nguyen, Amandine | Pais de Barros, Jean-Paul | Bouillet, Benjamin | Petit, Jean-Michel | Vergès, Bruno | Duvillard, Laurence

Edité par CCSD ; Elsevier -

IF 3.942. International audience. Objective: Phospholipids and sphingolipids play a critical role in the protective effects of HDL against atherosclerosis. These properties are impaired in patients with metabolic syndrome, before the development of diabetes. We thus investigated whether HDL from patients with metabolic syndrome but normal fasting glycaemia present abnormalities in their sphingophospholipid profile.Methods: Using liquid chromatography/tandem mass spectrometry, we quantified the different species of the main phospholipids and sphingolipids in the HDL2 and HDL3 from 26 obese patients with metabolic syndrome but normal fasting glycaemia and 50 controls.Results: Phosphatidylcholines, when expressed as the relative amount compared with total phospholipids and sphingolipids, were similar in both HDL2 and HDL3 in the two groups. Lysophosphatidylcholines were 41% (p = 0.0002) and 86% (p < 0.0001) higher in HDL2 and HDL3, respectively, from patients with metabolic syndrome than in those from controls. Phosphatidylinositols were also higher in HDL2 and HDL3 (respectively, +60 and + 103% (p < 0.0001)). In contrast, both HDL2 and HDL3 from patients with metabolic syndrome showed lower proportions of phosphatidylethanolamine-based plasmalogens (respectively -78 and - 73%, p < 0.0001), phosphatidylcholine-based plasmalogens (respectively - 44 and - 53%, p < 0.0001), d18: 1-sphingosine-1-phosphate (respectively - 52 and - 38%, p < 0.0001) and sphingomyelins (respectively - 19% (p < 0.0001) and -24% (p = 0.0006)), than did controls. Moreover, we observed a decrease in C18: 2 fatty acid-containing phospholipids and an increase in C20: 4 fatty acid-containing phospholipids.Conclusion: The sphingophospholipidome of HDL from normoglycaemic obese patients with metabolic syndrome is profoundly modified, before the dysregulation of glycaemia. Most of the changes observed have pejorative effect in terms of vascular protection. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

Consulter en ligne

Suggestions

Du même auteur

Impairment of the Ability of HDL From Patients With Metabolic Syndrome but Without Diabetes Mellitus to Activate eNOS: Correction by S1P Enrichment.

Archive ouverte | Denimal, Damien | CCSD

International audience. Objective-High-density lipoprotein (HDL) from nondiabetic patients with metabolic syndrome (MetS) displays abnormalities in their lipidome, such as triglyceride enrichment and sphingosine-1-p...

Les guidelines des sociétés européennes de diabétologie et d’hépatologie concernant l’exploration et la prise en charge de la stéatose hépatique non-alcoolique ne sont pas adaptées aux patients diabétiques de type 2

Archive ouverte | Petit, Jean-Michel | CCSD

International audience

Liver Fat Content in People with Pituitary Diseases: Influence of Serum IGF1 Levels

Archive ouverte | Nguyen, Amandine | CCSD

International audience. Non-alcoholic fatty liver disease (NAFLD) is commonly associated with obesity, metabolic syndrome, and type 2 diabetes. NAFLD is also seen in patients with endocrinopathies. However, the rela...

Chargement des enrichissements...